Trial record 1 of 1 for:    preferms
Previous Study | Return to List | Next Study

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. (PREFERMS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01623596
First received: June 18, 2012
Last updated: August 21, 2014
Last verified: August 2014
  Purpose

A 12 month study where 1000 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be in early stages of the disease and be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) for no more than 5 years total exposure. Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study.

Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.


Condition Intervention Phase
Relapsing Remitting Multiple Sclerosis
Drug: Fingolimod
Drug: Disease Modifying therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults Who Are in Early Stages of Treatment for Relapsing Remitting Multiple Sclerosis (PREFERMS)

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Retention on treatment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Retention on treatment over a 12 month period.


Secondary Outcome Measures:
  • Reasons for Discontinuation [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    To compare reasons for discontinuation in patients treated with fingolimod vs. DMT over 12 months of treatment

  • Adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Compare the occurrence and persistence of drug-related adverse events over 12 months of treatment

  • Cognitive impairment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Compare cognitive impairment measured by Symbol Digit Modalities Test scores.

  • Percent change in brain volume [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Compare percent change in brain volume in patients treated with fingolimod vs.DMTs as measured by MRI

  • Treatment satisfaction [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Compare medication satisfaction as measured by the Medication Satisfaction Questionnaire


Estimated Enrollment: 852
Study Start Date: June 2012
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fingolimod Drug: Fingolimod
Active Comparator: Disease Modifying Therapy
2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
Drug: Disease Modifying therapy

Detailed Description:

1000 Patients in early stages of treatment for relapsing remitting MS will be randomized 1:1 to fingolimod or approved first line DMTs. Patients must be either treatment naive or have received treatment with only one class of treatment (interferon beta preparation or glatiramer acetate) for no more than five years total exposure. Patients previously treated with DMT and randomized to the DMT arm may not remain on the same treatment for the study and will have to switch to a different class (i.e., previously treated with glatiramer acetate will switch to interferon beta preparaption, previously treated with interferon beta preparation will swtich to glatiramer acetate).

Entry criteria at screening include but are not limited to, age 18-65, diagnosis with RRMS, EDSS < or equal to 6, not pregnant or planning pregnancy and women of childbearing potential willing to use contraception throughout the study.

Exclusion criteria include but are not limited to - prior exposure to fingolimod, history of malignancy within 5 years, other than RRMS types of MS, other diseases of the immune system, active macular edema, systemic bacterial, viral or fungal infections, patients without vaccine against varicella zoster, receipt of live or attentuated vaccines within a month of screening, history of various cardiac conditions, presence of certain ECG abnormalities, resting heart rate < 45 bpm, symptomatic bradycardia, recurrent syncope, severe untreated sleep apnea, severe pulmonary conditions, various hepatic conditions, certain neurologic disorders, pregnancy.

Patients may switch treatment before 3 months for safety reasons only, after 3 months for safety, efficacy, tolerability or convenience. Treatment switch during the study may be to any of study approved treatments irrespective of prior treatment.

Patients randomized to fingolimod will need to have 6 hours of observation for signs and symptoms of bradycardia following administration of the first dose. Extended observation or overnight observation may be necessary under certain circumstances. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI. Exploratory objectives include annualized relapse rate, OCT, MRI evaluations, biomarkers and patient reported outcome measures.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent must be obtained prior to any assessment being performed.
  2. Male and female patients aged 18-65 years inclusive.
  3. Patients diagnosed with relapsing remitting MS, defined by the 2010 revised McDonald criteria
  4. EDSS score of less than or equal to 6.
  5. Patients naive to treatment or who have been treated with no more than one class of DMT previously (interferon β preparation or glatiramer acetate); total treatment exposure ≤ 5 years; and who, per investigator judgment, may benefit from a change of treatment class.
  6. Women of childbearing potential must have a negative urine and serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening and at baseline.
  7. Before entry women must be:

    • Post menopausal for at least 1 year, or
    • Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation or otherwise incapable of pregnancy, or
    • Practicing a highly effective method of birth control if sexually active, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner sterilization consistent with local regulations regarding use of birth control methods for patients participating in clinical trials, for the duration of their participation in the study, or
    • Not heterosexually active (patients who are not heterosexually active at screening must agree to utilize a highly effective method of birth control if they become heterosexually active during their participation in the study)

Exclusion Criteria:

  1. Use of other investigational drugs within 30 days of screening.
  2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
  3. Prior exposure to fingolimod.
  4. History or presence of malignancy of any organ system (other than successfully treated basal or squamous cell carcinoma of the skin or stage 0 carcinoma of the cervix), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  5. Patients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Primary Progressive MS (PPMS).
  6. Patients with a history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome.
  7. Patients who have been treated with:

    • Natalizumab, methotrexate, azathioprine, mitoxantrone, cladribine, cyclophosphamide, chronic treatment (more than 6 months) with immunoglobulins, or pulse of corticosteroids

  8. History of treatment with both classes of approved first line DMT (interferon β preparation and glatiramer acetate).
  9. Patients with uncontrolled diabetes mellitus (HbA1c > 7%).
  10. Diagnosis of macular edema during the screening phase. Patients with a history of macular edema will be allowed to enter the study provided that they do not have macular edema at the screening visit.
  11. Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.
  12. Patients without history of chickenpox or without vaccination against varicella-zoster virus at screening (patients may be vaccinated and rescreened one month or longer after vaccination).
  13. Patients who have received any live or live attenuated vaccines (including for varicella-zoster or measles) within 1 month prior to baseline .
  14. Patients with any medically unstable condition as assessed by the investigator.
  15. Patients with a history of the following cardiovascular conditions:

    • Cardiac arrest.
    • myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure (Appendix 3).
    • Congestive heart failure.
    • Hypertension that is not controlled with prescribed medications. These patients may be rescreened if blood pressure is stabilized with treatment.
    • Cerebrovascular disease.
    • History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker.
    • Patients at higher risk of symptomatic bradycardia or heart block because of a coexisting medical condition or certain concomitant medications.
    • Patients with prolonged QTc interval at baseline (corrected QT interval > 450 ms in males and > 470 ms in females), before dosing or during the observation period, or at additional risk for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on a concomitant therapy with QT prolonging drugs with a known risk of Torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin).
    • Patients receiving class Ia or Class III antiarrhythmic drugs
    • Patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart-rate slowing calcium channel blockers such as diltiazem, verapamil or digoxin). The possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction should be evaluated by the physician prescribing these drugs before initiating fingolimod treatment.
    • History of sick sinus syndrome or sinoatrial heart block.
    • Resting heart rate of < 45 bpm or symptomatic bradycardia
    • Recurrent syncope
    • Severe untreated sleep apnea
  16. Patients with severe pulmonary conditions (including severe respiratory disease, pulmonary fibrosis, active tuberculosis, severe or poorly controlled asthma).
  17. Patients with any of the following hepatic conditions:

    • Chronic liver or biliary disease
    • Total bilirubin greater than upper limit of normal (ULN) at screening unless in the context of Gilbert's syndrome
    • Conjugated bilirubin greater than the ULN at screening
    • AST (SGOT), ALT (SGPT) greater than 3 times ULN at screening
    • Alkaline phosphatase (AP) greater than 1.5 times the ULN at screening
  18. Serum creatinine greater than 2.0 mg/dL (176.5 µmol/L) at screening.
  19. Patients with the following neurological/psychiatric disorders:

    • History of substance abuse (drug or alcohol) in the past five years as determined by the investigator
    • Progressive neurological disorder other than MS which may affect study participation as determined by the investigator
    • Any serious psychiatric condition that may interfere with the patient's ability to cooperate and comply with the study procedures as determined by the investigator
  20. Women who are pregnant or nursing (lactating) or planning to become pregnant.
  21. Any condition that in the opinion of the investigator, would compromise the well-being of the patient or the conduct of the study, or prevent the patient from meeting or performing study requirements.
  22. Pre-planned surgery or medical procedure that would interfere with the conduct of the study.
  23. Employee of the sponsor, investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01623596

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Birmingham, Alabama, United States, 35233-0271
Novartis Investigative Site
Cullman, Alabama, United States, 35058
Novartis Investigative Site
Huntsville, Alabama, United States, 35801
United States, Arizona
Novartis Investigative Site
Gilbert, Arizona, United States, 85234
Novartis Investigative Site
Phoenix, Arizona, United States, 85032
Novartis Investigative Site
Phoenix, Arizona, United States, 85006
Novartis Investigative Site
Phoenix, Arizona, United States, 85004
Novartis Investigative Site
Sun City, Arizona, United States, 85351
Novartis Investigative Site
Tucson, Arizona, United States, 85741
United States, Arkansas
Novartis Investigative Site
Sherwood, Arkansas, United States, 72120
United States, California
Novartis Investigative Site
Fullerton, California, United States, 92835
Novartis Investigative Site
Oceanside, California, United States, 92056
Novartis Investigative Site
Sacramento, California, United States, 95816
Novartis Investigative Site
San Francisco, California, United States, 94117
Novartis Investigative Site
Travis AFB, California, United States, 94535
Novartis Investigative Site
Walnut Creek, California, United States, 94598
United States, Colorado
Novartis Investigative Site
Basalt, Colorado, United States, 81621
Novartis Investigative Site
Boulder, Colorado, United States, 80304
Novartis Investigative Site
Colorado Springs, Colorado, United States, 80920
Novartis Investigative Site
Denver, Colorado, United States, 80209
Novartis Investigative Site
Denver, Colorado, United States, 80210
Novartis Investigative Site
Fort Collins, Colorado, United States, 80524
Novartis Investigative Site
Fort Collins, Colorado, United States, 80528
United States, Connecticut
Novartis Investigative Site
Fairfield, Connecticut, United States, 06824
Novartis Investigative Site
New London, Connecticut, United States, 06320
United States, Delaware
Novartis Investigative Site
Dover, Delaware, United States, 19901
United States, Florida
Novartis Investigative Site
Atlantis, Florida, United States, 33462-6608
Novartis Investigative Site
Bradenton, Florida, United States, 32405
Novartis Investigative Site
Delray Beach, Florida, United States, 33445
Novartis Investigative Site
Fort Lauderdale, Florida, United States, 33308
Novartis Investigative Site
Fort Walton Beach, Florida, United States, 32547
Novartis Investigative Site
Gainesville, Florida, United States, 32607
Novartis Investigative Site
Hialeah, Florida, United States, 33012
Novartis Investigative Site
Hollywood, Florida, United States, 33021
Novartis Investigative Site
Jacksonville, Florida, United States, 32216
Novartis Investigative Site
Miami, Florida, United States, 33015
Novartis Investigative Site
North Palm Beach, Florida, United States, 33408
Novartis Investigative Site
Ocala, Florida, United States, 34471
Novartis Investigative Site
Orlando, Florida, United States, 32806
Novartis Investigative Site
Palm Harbor, Florida, United States, 34684
Novartis Investigative Site
Plantation, Florida, United States, 33324
Novartis Investigative Site
Pompano Beach, Florida, United States, 33060
Novartis Investigative Site
Ponte Vedra Beach, Florida, United States, 32082-4627
Novartis Investigative Site
Port Charlotte, Florida, United States, 33952
Novartis Investigative Site
Port Orange, Florida, United States, 32127
Novartis Investigative Site
Sarasota, Florida, United States, 34239
Novartis Investigative Site
Sarasota, Florida, United States, 34233
Novartis Investigative Site
Sarasota, Florida, United States, 34243
Novartis Investigative Site
South Miami, Florida, United States, 33143
Novartis Investigative Site
St. Petersburg, Florida, United States, 33713
Novartis Investigative Site
Tallahassee, Florida, United States, 32308
Novartis Investigative Site
Tampa, Florida, United States, 33609
Novartis Investigative Site
Tampa, Florida, United States, 33612
Novartis Investigative Site
West Palm Beach, Florida, United States, 33407
United States, Georgia
Novartis Investigative Site
Atlanta, Georgia, United States, 30312
Novartis Investigative Site
Atlanta, Georgia, United States, 30302
Novartis Investigative Site
Columbus, Georgia, United States, 31909
Novartis Investigative Site
Columbus, Georgia, United States, 31904
Novartis Investigative Site
Decatur, Georgia, United States, 30083
Novartis Investigative Site
Suwanee, Georgia, United States, 30024
United States, Illinois
Novartis Investigative Site
Champaign, Illinois, United States, 61820
Novartis Investigative Site
Downers Grove, Illinois, United States, 60575
Novartis Investigative Site
Evanston, Illinois, United States, 60201
Novartis Investigative Site
Flossmoor, Illinois, United States, 60422
Novartis Investigative Site
Lake barrington, Illinois, United States, 60010
Novartis Investigative Site
Northbrook, Illinois, United States, 60062
United States, Indiana
Novartis Investigative Site
Anderson, Indiana, United States, 46011
Novartis Investigative Site
Ft. Wayne, Indiana, United States, 46805
Novartis Investigative Site
Indianapolis, Indiana, United States, 46256
Novartis Investigative Site
Indianapolis, Indiana, United States, 46227
United States, Iowa
Novartis Investigative Site
Des Moines, Iowa, United States, 50314-2611
United States, Kansas
Novartis Investigative Site
Lenexa, Kansas, United States, 66212
Novartis Investigative Site
Overland Park, Kansas, United States
Novartis Investigative Site
Wichita, Kansas, United States, 67214
United States, Kentucky
Novartis Investigative Site
Hawesville, Kentucky, United States, 42384
Novartis Investigative Site
Lexington, Kentucky, United States, 40504
Novartis Investigative Site
Madisonville, Kentucky, United States, 42431
Novartis Investigative Site
Owensboro, Kentucky, United States, 42303
United States, Louisiana
Novartis Investigative Site
Alexandria, Louisiana, United States, 71301
Novartis Investigative Site
Baton Rouge, Louisiana, United States, 70809
Novartis Investigative Site
New Orleans, Louisiana, United States, 70115
United States, Maryland
Novartis Investigative Site
Annapolis, Maryland, United States, 21401
Novartis Investigative Site
Baltimore, Maryland, United States, 21201
Novartis Investigative Site
Fulton, Maryland, United States, 20759
Novartis Investigative Site
Hagerstown, Maryland, United States, 21741
United States, Massachusetts
Novartis Investigative Site
New Bedford, Massachusetts, United States, 02740
Novartis Investigative Site
North Dartmouth, Massachusetts, United States, 02747
Novartis Investigative Site
Springfield, Massachusetts, United States, 01104
Novartis Investigative Site
Watertown, Massachusetts, United States, 02472
Novartis Investigative Site
Worcester, Massachusetts, United States, 01665
Novartis Investigative Site
Worchester, Massachusetts, United States, 01608
United States, Michigan
Novartis Investigative Site
Clinton Township, Michigan, United States, 48035
Novartis Investigative Site
Grand Rapids, Michigan, United States
Novartis Investigative Site
Kalamazoo, Michigan, United States, 49007
Novartis Investigative Site
Rochester Hills, Michigan, United States, 48301
Novartis Investigative Site
Roseville, Michigan, United States, 48006
Novartis Investigative Site
Royal Oak, Michigan, United States, 48073
Novartis Investigative Site
Saginaw, Michigan, United States, 45604
Novartis Investigative Site
Southfield, Michigan, United States, 48034
Novartis Investigative Site
Traverse City, Michigan, United States, 49684-2340
Novartis Investigative Site
West Bloomfield, Michigan, United States, 48322
Novartis Investigative Site
Woodhaven, Michigan, United States, 48183
United States, Minnesota
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Novartis Investigative Site
Kansas City, Missouri, United States, 64111
Novartis Investigative Site
Nixa, Missouri, United States, 65714-7807
Novartis Investigative Site
North Kansas City, Missouri, United States, 64116
Novartis Investigative Site
St. Louis, Missouri, United States, 63104
Novartis Investigative Site
St. Louis, Missouri, United States, 63141
Novartis Investigative Site
Washington, Missouri, United States, 63090
United States, Montana
Novartis Investigative Site
Billings, Montana, United States, 59102
United States, Nevada
Novartis Investigative Site
Henderson, Nevada, United States, 89014
Novartis Investigative Site
Las Vegas, Nevada, United States, 89123
Novartis Investigative Site
Las Vegas, Nevada, United States, 89121
Novartis Investigative Site
Las Vegas, Nevada, United States, 89169-2578
Novartis Investigative Site
Las Vegas, Nevada, United States, 89144
Novartis Investigative Site
Reno, Nevada, United States, 89502
United States, New Jersey
Novartis Investigative Site
Bayonne, New Jersey, United States, 07002
Novartis Investigative Site
Flemington, New Jersey, United States, 08822
Novartis Investigative Site
Teaneck, New Jersey, United States, 07666
Novartis Investigative Site
Toms River, New Jersey, United States, 08755
United States, New Mexico
Novartis Investigative Site
Albuquerque, New Mexico, United States, 87108
United States, New York
Novartis Investigative Site
Albany, New York, United States, 12208
Novartis Investigative Site
Amherst, New York, United States, 14226
Novartis Investigative Site
Bronx, New York, United States, 10467-2490
Novartis Investigative Site
Brooklyn, New York, United States, 11206
Novartis Investigative Site
Kingston, New York, United States, 12401
Novartis Investigative Site
Latham, New York, United States, 12110
Novartis Investigative Site
New York, New York, United States, 10003
Novartis Investigative Site
New York, New York, United States, 10023
Novartis Investigative Site
New York, New York, United States, NY 10004
Novartis Investigative Site
Patchogue, New York, United States, 11772
Novartis Investigative Site
Plainview, New York, United States, 11803
Novartis Investigative Site
Staten Island, New York, United States, 10306
Novartis Investigative Site
Stony Brook, New York, United States, 11794-8161
United States, North Carolina
Novartis Investigative Site
Asheville, North Carolina, United States, 28806
Novartis Investigative Site
Charlotte, North Carolina, United States, 28207
Novartis Investigative Site
Charlotte, North Carolina, United States, 28204
Novartis Investigative Site
Charlotte, North Carolina, United States, 28209
Novartis Investigative Site
Greensboro, North Carolina, United States, 27401
Novartis Investigative Site
Greenville, North Carolina, United States, 27834
Novartis Investigative Site
Hendersonville, North Carolina, United States, 28792
Novartis Investigative Site
Mooresville, North Carolina, United States, 28117
Novartis Investigative Site
Raleigh, North Carolina, United States, 27607
Novartis Investigative Site
Salisbury, North Carolina, United States, 28144
Novartis Investigative Site
Wilmington, North Carolina, United States, 28401
Novartis Investigative Site
Winston Salem, North Carolina, United States, 27103
Novartis Investigative Site
Winston-Salem, North Carolina, United States, 27103
United States, North Dakota
Novartis Investigative Site
Grand Forks, North Dakota, United States, 58201
United States, Ohio
Novartis Investigative Site
Akron, Ohio, United States, 44320
Novartis Investigative Site
Akron, Ohio, United States, 44333
Novartis Investigative Site
Bellevue, Ohio, United States, 44811
Novartis Investigative Site
Canton, Ohio, United States, 44718
Novartis Investigative Site
Cincinnati, Ohio, United States, 45219
Novartis Investigative Site
Cleveland, Ohio, United States, 44119
Novartis Investigative Site
Columbus, Ohio, United States, 43221
Novartis Investigative Site
Dayton, Ohio, United States, 45408
Novartis Investigative Site
Franklin, Ohio, United States, 45005
Novartis Investigative Site
Toledo, Ohio, United States, 43623
United States, Oklahoma
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73104
Novartis Investigative Site
Oklahoma City, Oklahoma, United States, 73112
Novartis Investigative Site
Tulsa, Oklahoma, United States, 74136
United States, Oregon
Novartis Investigative Site
Corvallis, Oregon, United States, 97330
Novartis Investigative Site
Eugene, Oregon, United States, 97401
Novartis Investigative Site
Portland, Oregon, United States, 97239
Novartis Investigative Site
Portland, Oregon, United States, 97225
United States, Pennsylvania
Novartis Investigative Site
Erie, Pennsylvania, United States, 16507
Novartis Investigative Site
Greensburg, Pennsylvania, United States, 15601
Novartis Investigative Site
Hershey, Pennsylvania, United States, 17033
Novartis Investigative Site
Indiana, Pennsylvania, United States, 15701
Novartis Investigative Site
Monaca, Pennsylvania, United States, 15061
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19107
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19107-5098
Novartis Investigative Site
Pittsburg, Pennsylvania, United States, 15212
Novartis Investigative Site
Tarentum, Pennsylvania, United States, 15084
United States, Rhode Island
Novartis Investigative Site
Cranston, Rhode Island, United States, 02920
Novartis Investigative Site
Johnston, Rhode Island, United States, 02919
Novartis Investigative Site
Providence, Rhode Island, United States, 02905
United States, South Carolina
Novartis Investigative Site
Beufort, South Carolina, United States, 29902
Novartis Investigative Site
Indian Land, South Carolina, United States, 29707
Novartis Investigative Site
Spartanburg, South Carolina, United States
Novartis Investigative Site
Spartanburg, South Carolina, United States, 29302
Novartis Investigative Site
Spartanburg, South Carolina, United States, 29307
United States, Tennessee
Novartis Investigative Site
Columbia, Tennessee, United States, 38401
Novartis Investigative Site
Cordova, Tennessee, United States, 38018
Novartis Investigative Site
Knoxville, Tennessee, United States, 37920
Novartis Investigative Site
Knoxville, Tennessee, United States, 37934
Novartis Investigative Site
Memphis, Tennessee, United States, 38119
Novartis Investigative Site
Nashville, Tennessee, United States, 37205
United States, Texas
Novartis Investigative Site
Colleyville, Texas, United States, 76034
Novartis Investigative Site
Dallas, Texas, United States, 75246
Novartis Investigative Site
Frisco, Texas, United States, 75035
Novartis Investigative Site
Houston, Texas, United States, 77074
Novartis Investigative Site
Houston, Texas, United States, 77036
Novartis Investigative Site
Houston, Texas, United States, 77030
Novartis Investigative Site
Lubbock, Texas, United States, 79410
Novartis Investigative Site
North Richland Hills, Texas, United States, 76180
Novartis Investigative Site
Plano, Texas, United States, 75075
Novartis Investigative Site
Round Rock, Texas, United States, 78681
Novartis Investigative Site
San Antonio, Texas, United States, 78229
United States, Utah
Novartis Investigative Site
Orem, Utah, United States, 84058
United States, Virginia
Novartis Investigative Site
Alexandria, Virginia, United States, 22310
Novartis Investigative Site
Charlottesville, Virginia, United States, 22911
Novartis Investigative Site
Norfolk, Virginia, United States, 23502
Novartis Investigative Site
Norfolk, Virginia, United States, 23507
Novartis Investigative Site
Richmond, Virginia, United States, 23226
Novartis Investigative Site
Roanoke, Virginia, United States, 24014
Novartis Investigative Site
Vienna, Virginia, United States, 22182
United States, Washington
Novartis Investigative Site
Bellingham, Washington, United States, 98225
Novartis Investigative Site
Bothell, Washington, United States, 98011
Novartis Investigative Site
Lynwood, Washington, United States, 98036
Novartis Investigative Site
Seattle, Washington, United States, 98101
Novartis Investigative Site
Seattle, Washington, United States, 98195
Novartis Investigative Site
Spokane, Washington, United States, 99204
Novartis Investigative Site
Tacome, Washington, United States, 98405
United States, West Virginia
Novartis Investigative Site
Morgantown, West Virginia, United States, 26506-9260
Novartis Investigative Site
Morgantown, West Virginia, United States, 26501
United States, Wisconsin
Novartis Investigative Site
Neenah, Wisconsin, United States, 54956
United States, Wyoming
Novartis Investigative Site
Casper, Wyoming, United States, 82601
Puerto Rico
Novartis Investigative Site
Guaynabo, Puerto Rico, 00969
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01623596     History of Changes
Other Study ID Numbers: CFTY720DUS09
Study First Received: June 18, 2012
Last Updated: August 21, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Fingolimod
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 20, 2014